

GUFIC BIOSCIENCES LIMITED						
Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069						
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2015						
	Rs. In Lacs					
Particulars	Quarter Ended 30.09.2015 Unaudited	Quarter Ended 30.06.2015 Unaudited	Quarter Ended 30.09.2014 Unaudited	Period Ended 30.09.2015 Unaudited	Period Ended 30.09.2014 Unaudited	For the Year Ended 31.03.2015 Audited
<b>INCOME:</b>						
Net Sales / Income from Operations (Net of Excise Duty)	5130.73	3759.20	4263.81	8889.93	8171.87	15142.61
Other Operating Income	10.85	8.40	12.58	19.25	14.64	32.53
<b>Total Income from Operations (Net)</b>	<b>5141.58</b>	<b>3767.60</b>	<b>4276.39</b>	<b>8909.18</b>	<b>8186.50</b>	<b>15175.14</b>
<b>EXPENSES:</b>						
Cost of Materials Consumed	2044.78	1755.99	2262.43	3800.77	3909.38	6579.76
Purchase of Stock-in-Trade	786.09	557.29	272.73	1343.38	826.17	1670.77
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(220.69)	(680.64)	(48.91)	(901.33)	(50.56)	(130.68)
Employee Benefits Expenses	846.15	745.81	457.80	1591.96	825.33	1933.33
Depreciation and Amortisation Expenses	94.56	92.36	103.11	186.92	202.35	385.21
Other Expenses	1240.56	1023.04	907.55	2263.60	1857.44	3675.26
<b>Total Expenses</b>	<b>4791.44</b>	<b>3493.85</b>	<b>3954.71</b>	<b>8285.30</b>	<b>7570.11</b>	<b>14113.66</b>
<b>Profit from Operations before Other Income, finance costs and Exceptional Items</b>	<b>350.14</b>	<b>273.75</b>	<b>321.69</b>	<b>623.88</b>	<b>616.39</b>	<b>1061.48</b>
Other Income	33.36	1.98	(11.88)	35.34	17.36	37.18
<b>Profit from ordinary activities before finance costs and exceptional items</b>	<b>383.50</b>	<b>275.73</b>	<b>309.81</b>	<b>659.22</b>	<b>633.76</b>	<b>1098.66</b>
Finance Costs	122.80	114.73	110.94	237.53	216.78	446.08
<b>Profit from ordinary activities after finance costs but before exceptional items</b>	<b>260.69</b>	<b>161.00</b>	<b>198.87</b>	<b>421.69</b>	<b>416.97</b>	<b>652.59</b>
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit from Ordinary Activities Before Tax</b>	<b>260.69</b>	<b>161.00</b>	<b>198.87</b>	<b>421.69</b>	<b>416.97</b>	<b>652.59</b>
Current Tax	112.20	75.00	103.61	187.20	178.61	278.61
Deferred Tax	(16.60)	(18.03)	(27.65)	(34.63)	(3.91)	(48.84)
Short/(Excess) Tax Provisions of Earlier Years	0.00	0.00	4.43	0.00	4.43	7.08
<b>Net Profit from Ordinary Activities After Tax</b>	<b>165.09</b>	<b>104.03</b>	<b>118.47</b>	<b>269.12</b>	<b>237.84</b>	<b>415.74</b>
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
<b>Net Profit for the Period</b>	<b>165.09</b>	<b>104.03</b>	<b>118.47</b>	<b>269.12</b>	<b>237.84</b>	<b>415.74</b>
Paid up Equity Share Capital (Face Value of Rs 1/- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	2205.61	2040.52	1796.92	2205.61	1796.92	1936.49
<b>E.P.S</b>	<b>0.21</b>	<b>0.13</b>	<b>0.15</b>	<b>0.35</b>	<b>0.31</b>	<b>0.54</b>
<b>Public Shareholding</b>						
- Number of Shares of Rs 1/- Each	23222355	23222355	23222355	23222355	23222355	23222355
- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
<b>Promoters and Promoter group Shareholding</b>						
<b>a) Pledged / Encumbered</b>						
- Number of Shares of Rs 1/- Each	0	0	0	0	0	0
- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
<b>b) Non - Encumbered</b>						
- Number of Shares of Rs 1/- Each	54127645	54127645	54127645	54127645	54127645	54127645
- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%

*Behar*

**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 30.09.2015**

Rs. In Lacs

Particulars	Quarter Ended 30.09.2015 Unaudited	Quarter Ended 30.06.2015 Unaudited	Quarter Ended 30.09.2014 Unaudited	Period Ended 30.09.2015 Unaudited	Period Ended 30.09.2014 Unaudited	For the Year Ended 31.03.2015 Audited
<b>SEGMENT REVENUE</b>						
Sales & Service						
Pharma	5040.12	3650.22	3900.81	8690.34	7455.77	13922.95
Consumer	90.61	108.98	363.00	199.59	716.09	1219.66
<b>Total</b>	<b>5130.73</b>	<b>3759.20</b>	<b>4263.81</b>	<b>8889.93</b>	<b>8171.87</b>	<b>15142.61</b>
Unallocated Income	44.21	10.38	0.70	54.59	32.00	69.71
<b>Total Segment Revenue</b>	<b>5174.94</b>	<b>3769.58</b>	<b>4264.51</b>	<b>8944.52</b>	<b>8203.87</b>	<b>15212.32</b>
<b>SEGMENT RESULTS</b>						
Pharma	970.22	720.92	760.68	1691.14	1453.88	2701.05
Consumer	10.41	12.04	38.32	22.45	75.62	136.97
<b>TOTAL</b>	<b>980.63</b>	<b>732.96</b>	<b>798.99</b>	<b>1713.59</b>	<b>1529.50</b>	<b>2838.02</b>
Less: Unallocated over heads	502.58	364.87	386.07	867.46	693.39	1354.15
Finance Charges	122.80	114.73	110.94	237.53	216.78	446.08
Depreciation	94.56	92.36	103.11	186.92	202.35	385.21
Tax provision	95.60	56.97	80.40	152.57	179.13	236.85
<b>Net Profit after Tax</b>	<b>165.09</b>	<b>104.03</b>	<b>118.47</b>	<b>269.12</b>	<b>237.84</b>	<b>415.74</b>

**UNAUDITED STATEMENT OF ASSETS AND LIABILITIES**


(Rs in Lacs)

Particulars	AS AT 30.09.2015 Unaudited	AS AT 30.09.2014 Unaudited	AS AT 31.03.2015 Audited
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholder's Funds</b>			
a) Share Capital	773.50	773.50	773.50
b) Reserves and Surplus	2,205.61	1,796.92	1,936.49
<b>Sub-total - Shareholder's Funds</b>	<b>2979.11</b>	<b>2570.42</b>	<b>2709.99</b>
<b>Non-current liabilities</b>			
a) Long-term borrowings	819.20	1,151.80	1,150.34
b) Deferred tax liabilities ( Net )	120.10	159.34	154.73
c) Other long-term liabilities	466.82	163.50	212.27
d) Long-term provisions	147.86	141.90	140.50
<b>Sub-total - Non-current liabilities</b>	<b>1553.98</b>	<b>1616.54</b>	<b>1657.85</b>
<b>Current liabilities</b>			
a) Short-term borrowings	2,707.46	1,604.88	1,790.42
b) Trade payables	5,752.77	5,537.66	4,953.33
c) Other current liabilities	1,586.37	1,466.87	1,301.22
d) Short-term provisions	448.59	370.76	315.97
<b>Sub-total - Current liabilities</b>	<b>10495.19</b>	<b>8980.17</b>	<b>8360.94</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>15028.28</b>	<b>13167.13</b>	<b>12728.78</b>
<b>ASSETS</b>			
<b>Non-current assets</b>			
a) Fixed assets	2,367.75	2,582.28	2,510.71
b) Non-current investments	0.93	0.92	0.93
c) Long-term loans and advances	804.15	762.03	759.75
d) Other non-current assets	395.89	264.58	282.58
<b>Sub-total - Non-Current assets</b>	<b>3568.72</b>	<b>3609.83</b>	<b>3553.97</b>
<b>Current assets</b>			
a) Current investments			
b) Inventories	4,901.65	3,367.87	3,680.14
c) Trade receivables	4,651.75	4,078.01	3,324.30
d) Cash and cash equivalents	564.62	211.86	620.63
e) Short-term loans and advances	1,341.54	1,899.56	1,549.74
<b>Sub-total - Current assets</b>	<b>11459.56</b>	<b>9557.30</b>	<b>9174.81</b>
<b>TOTAL - ASSETS</b>	<b>15028.28</b>	<b>13167.13</b>	<b>12728.78</b>

**Notes forming part of the un-audited financial results for the quarter ended September 30, 2015**

1. The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on November 09, 2015.
2. For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2015.
3. *Disclosure about investor complaints:* Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on September 30, 2015: Nil.
4. Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board  
Gufic Biosciences Limited

  
Praveer Choksi  
Executive Director

Mumbai dated November 09, 2015